Skip to main content
. Author manuscript; available in PMC: 2025 Sep 10.
Published in final edited form as: Nat Med. 2025 Aug 14;31(11):3668–3674. doi: 10.1038/s41591-025-03875-5

Extended Data Table 6 |.

Toxicities resulting in serious adverse events (SAEs), determined by the treating physician to be related to the treatment, reported among patients who received protocol therapy

Adverse Event Any Grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Adrenal insufficiency 2 (7%) 0 1 1 0 0
Pancreatitis 2 (7%) 0 0 2 0 0
Creatinine phosphokinase increased 1 (4%) 0 0 1 0 0
Cardiac troponin I increased 1 (4%) 1 0 0 0 0
Colitis 1 (4%) 0 0 1 0 0
Diarrhea 1 (4%) 0 0 1 0 0
Fever 1 (4%) 0 1 0 0 0
Generalized muscle weakness 1 (4%) 0 1 0 0 0
Immune-mediated duodenitis 1 (4%) 0 0 1 0 0
Lung infection 1 (4%) 0 0 0 1 0
MS/connective tissue disorder 1 (4%) 0 0 1 0 0
Myositis 1 (4%) 0 0 1 0 0
Upper GI hemorrhage 1 (4%) 0 0 1 0 0

Adverse event severity was scored using National Cancer Institute CTCAE version 4.0.